50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Topiramate leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (high certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher seizure freedom compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Topiramate leads to higher treatment withdrawal compared with placebo (high certainty).
1 finding from 1 review
Adverse events ‐ weight loss · people with drug‐resistant focal epilepsy
Topiramate may leads to higher adverse effects ‐ weight loss/decrease compared with placebo (low certainty).
1 finding from 1 review
Paraesthesia · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ paraesthesia compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy
Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).
1 finding from 1 review
Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties · people with drug‐resistant focal epilepsy
Topiramate probably leads to higher adverse effects ‐ difficulty with concentration/concentration… compared with placebo (moderate certainty).
1 finding from 1 review
Annual rate of change in % predicted FEV1 All participants · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FEV1 Subgroup: under 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FEV1 Subgroup: over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC All participants · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Under 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Over 13 years of age · adults and children with cystic fibrosis
1 finding from 1 review
Transmission‐related outcomes: hospitalization ‐ Number or proportion of hospital admissions · adults and children with cystic fibrosis
Summary of findings: non‐steroidal anti‐inflammatory drugs showed no clear difference in proportion with at least 1 hospital admission compared with placebo (moderate certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Tiagabine leads to higher 50% or greater reduction in seizure frequency (Intention‐to‐treat… compared with placebo control (high certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Tiagabine probably leads to higher treatment withdrawal compared with placebo control (moderate certainty).
1 finding from 1 review
Dizziness · people with drug‐resistant focal epilepsy
Tiagabine probably leads to higher dizziness compared with placebo control (moderate certainty).
1 finding from 1 review
Fatigue · people with drug‐resistant focal epilepsy
Tiagabine showed no clear difference in fatigue compared with placebo control (moderate certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Tiagabine showed no clear difference in nausea compared with placebo control (low certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Tiagabine showed no clear difference in somnolence compared with placebo control (moderate certainty).
1 finding from 1 review